CA2618741C - Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections - Google Patents

Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections Download PDF

Info

Publication number
CA2618741C
CA2618741C CA2618741A CA2618741A CA2618741C CA 2618741 C CA2618741 C CA 2618741C CA 2618741 A CA2618741 A CA 2618741A CA 2618741 A CA2618741 A CA 2618741A CA 2618741 C CA2618741 C CA 2618741C
Authority
CA
Canada
Prior art keywords
group
substituted
independently selected
compound
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2618741A
Other languages
English (en)
French (fr)
Other versions
CA2618741A1 (en
Inventor
Stephane Ciblat
Evelyne Dietrich
Ting Kang
Yanick Lafontaine
Adel Rafai Far
Ranga Reddy
Yannick Stephane Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targanta Therapeutics Inc
Original Assignee
Targanta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targanta Therapeutics Inc filed Critical Targanta Therapeutics Inc
Publication of CA2618741A1 publication Critical patent/CA2618741A1/en
Application granted granted Critical
Publication of CA2618741C publication Critical patent/CA2618741C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2618741A 2005-08-11 2006-08-11 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections Expired - Lifetime CA2618741C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70714505P 2005-08-11 2005-08-11
US60/707,145 2005-08-11
PCT/IB2006/004128 WO2007096703A2 (en) 2005-08-11 2006-08-11 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections

Publications (2)

Publication Number Publication Date
CA2618741A1 CA2618741A1 (en) 2007-08-30
CA2618741C true CA2618741C (en) 2014-03-25

Family

ID=38437733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2618741A Expired - Lifetime CA2618741C (en) 2005-08-11 2006-08-11 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections

Country Status (11)

Country Link
US (1) US8404664B2 (enExample)
EP (1) EP1928890B1 (enExample)
JP (1) JP5368092B2 (enExample)
KR (1) KR101327635B1 (enExample)
CN (1) CN101282981B (enExample)
AU (1) AU2006339058B2 (enExample)
BR (1) BRPI0614758A2 (enExample)
CA (1) CA2618741C (enExample)
EA (1) EA016059B1 (enExample)
IL (1) IL189270A (enExample)
WO (1) WO2007096703A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
US8524691B2 (en) 2008-08-13 2013-09-03 The Medicines Company Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
JP6029596B2 (ja) * 2011-02-24 2016-11-24 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング ビスホスホネートプロドラッグ
FR2973378B1 (fr) * 2011-03-28 2013-10-04 Atlanthera Derives d'acide hydroxybisphosphonique bifonctionnels
PE20160715A1 (es) * 2013-05-31 2016-08-01 Genentech Inc Anticuerpos frente a acidos teicoicos de pared y conjugados
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
CN104524928A (zh) * 2014-12-30 2015-04-22 上海锅炉厂有限公司 一种捕集二氧化碳的吸收剂
CN107011380A (zh) * 2016-01-28 2017-08-04 臧伟 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用
RU2020102511A (ru) * 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
JP7501960B2 (ja) * 2018-07-09 2024-06-18 バイオビンク エルエルシー ビスホスホネート・キノロン複合体及びそれらの用途
CN119291074A (zh) * 2024-11-12 2025-01-10 重庆华邦胜凯制药有限公司 分离检测利福喷汀中间体z1及其杂质的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR208F (enExample) 1964-07-31
US4261891A (en) 1965-08-24 1981-04-14 Ciba-Geigy Corporation Antibiotically active rifamycin derivatives
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
IT1056272B (it) 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
AU536524B2 (en) * 1979-06-28 1984-05-10 Gruppo Lepetit S.P.A. Water soluble hydrozones of 3-formylifamyan
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2746041B2 (ja) * 1992-02-14 1998-04-28 三菱化学株式会社 新規なステロイド誘導体
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
JPH093080A (ja) * 1995-04-21 1997-01-07 Sumitomo Pharmaceut Co Ltd 新規な骨親和性エストロゲン誘導体
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
CA2267984A1 (en) * 1996-10-09 1998-04-16 Elizanor Biopharmaceuticals, Inc. Diphosphonate therapeutic compounds
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6900204B2 (en) 2001-09-06 2005-05-31 Activbiotics, Inc. Antimicrobial agents and uses thereof
US7122525B2 (en) 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7078399B2 (en) 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
MXPA06002088A (es) 2003-08-22 2006-08-11 Activbiotics Inc Analogos de rifamicina y usos de los mismos.
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
WO2005070940A2 (en) 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
EP1723150A1 (en) 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7256187B2 (en) 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7250413B2 (en) 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
US7202246B2 (en) 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
CA2574307A1 (en) 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections

Also Published As

Publication number Publication date
EA016059B1 (ru) 2012-01-30
EP1928890B1 (en) 2013-04-03
CN101282981B (zh) 2012-09-26
AU2006339058B2 (en) 2012-09-06
JP2009505974A (ja) 2009-02-12
EP1928890A4 (en) 2011-08-31
US8404664B2 (en) 2013-03-26
BRPI0614758A2 (pt) 2011-04-12
KR101327635B1 (ko) 2013-11-12
EP1928890A2 (en) 2008-06-11
US20110263534A1 (en) 2011-10-27
IL189270A0 (en) 2008-08-07
CN101282981A (zh) 2008-10-08
WO2007096703A3 (en) 2008-01-03
KR20080035687A (ko) 2008-04-23
IL189270A (en) 2015-05-31
CA2618741A1 (en) 2007-08-30
AU2006339058A1 (en) 2007-08-30
WO2007096703A2 (en) 2007-08-30
JP5368092B2 (ja) 2013-12-18
EA200800570A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
US8524691B2 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
FI89366B (fi) Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
JP5823862B2 (ja) イミダゾ［１，２‐α］ピリジニルビスホスホネート
EP1928890B1 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
EP1252169A1 (en) Process for making geminal bisphosphonates
US8946144B2 (en) Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
SK144694A3 (en) Thio-substituted nitrogen containing heterocyclic phosphate compounds for treating calcium and phosphate metabolism
Tanaka et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
WO2007138381A2 (en) Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
US20080287396A1 (en) Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections
US6207655B1 (en) Bis-phosphonate confugates with alkylating moieties having antitumor activity
EP0589473A1 (en) Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and their use in pharmaceutical compositions
IE911165A1 (en) Novel compounds
IL113246A (en) Bisphosphonates and pharmaceutical compositions containing them
Eisner Aminobisphosphonates and their derivatives: Traditional uses and novel applications

Legal Events

Date Code Title Description
EEER Examination request